HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warnings Target Companies US-Wide For Selling CBD Products That Violate Federal Law

Executive Summary

CHART: The agency sent out 15 warning letters on 25 November, citing companies in 10 states for selling unapproved and misbranded CBD drug products in the guise of dietary supplements and cosmetics.

You may also be interested in...



FDA’s Cannabidiol Crackdown: What Do Warning Letters Say About CBD In Cosmetics?

Cannabidiol (CBD) represents an intriguing opportunity for cosmetics, without the statutory obstacles faced by food and dietary supplement companies. Cosmetics marketers are taking advantage, but the FDA’s recent warning letter blitz is a reminder that CBD-infused beauty products are bound by the same rules that apply to other cosmetics.

Tests Show CBD Levels In Some Supplements Don't Match Labeling

Seven of 10 CBD-containing supplement products tested in a lab did not contain the levels of CBD advertised on the label, says hemp, CBD and natural health product information publisher Remedy Reviews. Most products also were found to contain heavy metals.

FDA Warns 15 CBD Product Marketers For Violations, Cautions Consumers: CBD May Harm You

The agency announces that it cannot conclude cannabidiol is GRAS, potentially heading off GRAS notifications and making NDI notifications a likelier future for CBD use in the supplement sector if any “lawful pathway” is to be found. In addition to a barrage of warning letters to marketers of CBD products, the FDA issued a stark warning to consumers about potential hazards.

Related Content

Topics

UsernamePublicRestriction

Register

RS149468

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel